Product Description: Mipasetamab is an IgG1κ antibody targeting to AXL, a tyrosine kinase receptor and an TAM Receptor. Mipasetamab involves in synthesis of ADCT-601 (Mipasetamab uzoptirine), an AXL-targeted antibody-drug conjugate (ADC). ADCT-601 has anti-tumor activity[1].
Applications: Cancer-Kinase/protease
Formula: N/A
References: [1]Zammarchi F, et al. Preclinical Development of ADCT-601, a Novel Pyrrolobenzodiazepine Dimer-based Antibody-drug Conjugate Targeting AXL-expressing Cancers. Mol Cancer Ther. 2022 Apr 1;21(4):582-593.
CAS Number: 2361055-48-1
Molecular Weight: N/A
Compound Purity: 97.82
Research Area: Cancer
Solubility: 10 mM in DMSO
Target: ADC Antibody;TAM Receptor